Beijing Minhai Biotechnology Co., Ltd. announced that it will receive CNY 300,000,000 in an equity round of funding from existing investor, Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) on April 23, 2017. Pursuant to the transaction, the investor shall continue to hold 100% stake in the company. The company’s registered capital will increase from CNY 200,000,000 to CNY 500,000,000. The transaction has been approved at 16th session of the investor’ 5th directorate and is subject to its shareholders’ approval. The company reported total assets of CNY 909,167,200, total liabilities of CNY 731,281,300, net assets of CNY 177,885,900, revenues of CNY 374,455,900, and net profit of CNY 53,842,600 for the year ended December 31, 2016.